The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors play a key role in the treatment of type 2 diabetes mellitus. This meta-analysis aims to evaluate the efficacy and safety of their combination, emphatically focusing on the effects of treatment duration and add-on drugs. Methods: Seven databases were searched until June 2021 for randomized controlled trials with a duration of at least 12 weeks, evaluating the effects of combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors. Results: A total of eight eligible articles were included, pooling data retrieved from 1895 patients with type 2 diabetes mellitus. Compared to monotherapy, combination therapy resulted in a greater reduction in glycated haemoglobin (HbA1c), body weight, fasting plasma glucose (FPG), 2 h postprandial glucose (2 h PG), systolic blood pressure (SBP), body mass index (BMI) and low-density lipoprotein cholesterol (LDL-C). The decrease in HbA1c, body weight and FPG was maintained for more than 1 year, but these effects gradually regressed over time. The risk for hypoglycaemia was significantly increased with combination therapy. In addition, drug discontinuation, diarrhoea, injection-site-related events, nausea, vomiting and genital infections were more likely to occur in combination therapy. Conclusion: Glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor combination therapy showed superior effects on reducing HbA1c, body weight, FPG, 2 h PG, SBP, BMI and LDL-C, without major safety issues, when compared with monotherapy in patients with type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“This systematic review and meta-analysis has been performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Hutton et al., 2015).”
MethodGlobal aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697 · cited 1×
“Long-term disease may cause macrovascular and microvascular complications that seriously affect the quality of life of patients (Zheng et al., 2018).”
BackgroundDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“As most GLP-1RAs need to be frequently administered subcutaneously (once weekly, once daily or even twice daily), their long-term usage can cause injection-site-related events (Madsbad, 2016; Nauck et al., 2021), which will lead to lower compliance.”
BackgroundBuse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 1×
“GLP1RAs can inhibit appetite, induce thermogenesis of brown adipose tissue and browning adipocyte in white adipose tissue (Beiroa et al., 2014), which might counteract the adverse effect of SGLT-2is on weight loss.”
BackgroundDiscovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376 · cited 1×
“3.3 Summary of Outcomes 3.3.1 Efficacy Outcomes 3.3.1.1 HbA1c Overall, all 8 articles (Jabbour et al., 2018; Ludvik et al., 2018; Zinman et al., 2019; Ali et al., 2020; Blonde et al., 2020; JabbourTA B LE 1 |C ha ra ct er is tic s an d ba se lin e of th e st ud ie s in cl ud ed in th e m et aan al…”
BackgroundInfluential
Research works printed but not linked: 22
- Ali, 2020, Combination Therapy with Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients with Type 2 Diabetes, Diabetes Care, 43, 1234, 10.2337/dc18-2460 · DOI · Paper page
- Brown, 2019, A Review of the Mechanism of Action, Metabolic Profile and Haemodynamic Effects of Sodium-Glucose Co-Transporter-2 Inhibitors, Diabetes Obes. Metab., 21, 9, 10.1111/dom.13650 · DOI
- Busch, 2017, Combination SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy: A Complementary Approach to the Treatment of Type 2 Diabetes, Postgrad. Med., 129, 686, 10.1080/00325481.2017.1342509 · DOI · Paper page
- Castellana, 2019, Efficacy and Safety of GLP-1 Receptor Agonists as Add-On to SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Meta-Analysis, Sci. Rep., 9, 19351, 10.1038/s41598-019-55524-w · DOI · Paper page
- Deol, 2017, Combination Therapy with GLP-1 Analogues and SGLT-2 Inhibitors in the Management of Diabesity: The Real World Experience, Endocrine, 55, 173, 10.1007/s12020-016-1125-0 · DOI
- Díaz-Trastoy, 2020, GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-World Clinical Practice, Clin. Ther., 42, e1, 10.1016/j.clinthera.2019.12.012 · DOI
- Doumas, 2018, Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints, Curr. Pharm. Des., 24, 1879, 10.2174/1381612824666180604113653 · DOI
- Ferrannini, 2015, Energy Balance after Sodium-Glucose Cotransporter 2 Inhibition, Diabetes Care, 38, 1730, 10.2337/dc15-0355 · DOI · Paper page
- Gorgojo-Martínez, 2017, Real-World Effectiveness and Safety of Dapagliflozin Therapy Added to a GLP1 Receptor Agonist in Patients with Type 2 Diabetes, Nutr. Metab. Cardiovasc. Dis., 27, 129, 10.1016/j.numecd.2016.11.007 · DOI
- Guo, 2020, The Efficacy and Safety of Combinations of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes or Obese Adults: A Systematic Review and Meta-Analysis, Endocrine, 67, 294, 10.1007/s12020-019-02175-6 · DOI
- Harreiter, 2021, Combined Exenatide and Dapagliflozin Has No Additive Effects on Reduction of Hepatocellular Lipids Despite Better Glycaemic Control in Patients with Type 2 Diabetes Mellitus Treated with Metformin: EXENDA, a 24-Week, Prospective, Randomized, Placebo-Controlled Pilot Trial, Diabetes Obes. Metab., 23, 1129, 10.1111/dom.14319 · DOI · Paper page
- Jabbour, 2018, Safety and Efficacy of Exenatide once Weekly Plus Dapagliflozin once Daily Versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial, Diabetes Care, 41, 2136, 10.2337/dc18-0680 · DOI · Paper page
- Jia, 2019, Standards of Medical Care for Type 2 Diabetes in China 2019, Diabetes Metab. Res. Rev., 35, e3158, 10.1002/dmrr.3158 · DOI · Paper page
- Kim, 2021, Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study, Diabetes Metab. J., 10.4093/dmj.2021.0232 · DOI
- Li, 2021, SGLT-2 Inhibitors or GLP-1 Receptor Agonists for Adults with Type 2 Diabetes: A Clinical Practice Guideline, BMJ, 373, n1091, 10.1136/bmj.n1091 · DOI · Paper page
- Monami, 2014, Efficacy and Safety of Sodium Glucose Co-Transport-2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials, Diabetes Obes. Metab., 16, 457, 10.1111/dom.12244 · DOI · Paper page
- Patoulias, 2019, Glycemic Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist on Top of Sodium-Glucose Co-Transporter-2 Inhibitor Treatment Compared to Sodium-Glucose Co-Transporter-2 Inhibitor Alone: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Diabetes Res. Clin. Pract., 158, 107927, 10.1016/j.diabres.2019.107927 · DOI
- Rongfeng, 2020, Efficacy of Liraglutide Combined with Dapagliflozin in the Treatment of Overweight and Obese Patients with Type Ⅱ Diabetes Mellitus and its Effects on Pancreatic Islet Function (In Chinese), China J. Mod. Med., 16, 72, 10.3969/j.issn.1005-8982.2020.16.014 · doi:10.3969/j.issn.1005-8982.2020.16.014
- Saroka, 2015, Sglt-2 Inhibitor Therapy Added to Glp-1 Agonist Therapy in the Management of T2dm, Endocr. Pract., 21, 1315, 10.4158/EP15877.OR · DOI
- Tahrani, 2016, Pharmacology and Therapeutic Implications of Current Drugs for Type 2 Diabetes Mellitus, Nat. Rev. Endocrinol., 12, 566, 10.1038/nrendo.2016.86 · DOI · Paper page
- Trujillo, 2017, Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes, Pharmacotherapy, 37, 927, 10.1002/phar.1962 · DOI
- 2016, Global Report on Diabetes
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., Renoux, C., Suissa, S., & Azoulay, L. (2024) · BMJ · doi:10.1136/bmj-2023-078242 · Cited by 151
“12-17 However, these represent surrogate outcomes, and whether this combination is associated with a reduced risk of macrovascular and microvascular complications remains unclear.”
BackgroundAhmad, A., & Sabbour, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02192-4 · Cited by 25
Metadata
- Authors
- Li, C., Luo, J., Jiang, M., & Wang, K.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-02-04
- Volume
- 13
- Pages
- 838277-838277
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4210635201
- Cited by
- 96
- References
- 23
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Natural Science Foundation of China (81703427)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.3389/fphar.2022.838277
- The paper
- Li, C., Luo, J., Jiang, M., & Wang, K. (2022). The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.838277
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.